Financing ·
Enlivex Ltd. terminated a Securities Purchase Agreement with the Rain Foundation on September 22, 2026, ending plans…
ENLVEnlivex Ltd.
Enlivex Ltd. terminated a Securities Purchase Agreement with the Rain Foundation on September 22, 2026, ending plans to issue 66,666,667 ordinary shares in a private placement payable via RAIN tokens. The company exercised its termination rights and will not seek shareholder approval for the transaction. Enlivex Ltd. operates as a quality longevity company developing clinical-stage immunotherapy Allocetra™ while maintaining a prediction markets treasury strategy.